

FOR RELEASE April 1, 2024

Contact: Missy Kemp, mkemp@prevenciomed.com

Prevencio Announces Laboratory Partnership and Continued Commercialization with University of Maryland

KIRKLAND, WA — [Prevencio, Inc.](#) today announces a partnership and continued commercialization with University of Maryland for its highly accurate, AI-driven HART blood tests for heart-related disease and risk. The HART blood tests are available and can be ordered through your physician.

University of Maryland's Clinical Chemistry Research Lab is a CLIA-certified CAP-accredited high complexity diagnostic lab providing the highest quality of testing, service, and technology. The partnership incorporates the use of Microsoft's Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio's HART, AI-driven test reports.

"We are excited to partner with University of Maryland for our patient-use HART tests on Microsoft's secure cloud," stated Rhonda Rhyne, Prevencio's Chief Executive Officer. "Based on physician and patient feedback, there is a clear clinical need and benefit for our HART tests. They provide highly accurate results in an easy-to-understand report, allowing physicians and patients to monitor and detect changes in cardiac health conditions."

Prevencio's AI-driven HART tests were developed in partnership with Massachusetts General Hospital and have consistently demonstrated higher accuracy as compared to standard risk scores or standard-of-care tests.

About Prevencio HART Tests:

Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications.

Three Lead HART Tests:

1. HART CADhs™ – obstructive coronary artery disease diagnosis
2. HART CVE™ – 1-year risk of heart attack, stroke, or cardiac death
3. HART KD™ – Kawasaki disease diagnosis

HART test results have been published in 34 top-tier journals and leading cardiovascular meetings.

About Prevencio, Inc.:

Prevencio's value proposition is "Preventing the Preventable" — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than

standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. The company is headquartered in Kirkland, Washington.

www.PrevenioMed.com

Forward-Looking (Safe Harbor) Statement:

Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on HART technology and various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.

###